中国生物制药（01177）今日盘中大涨5.14%，引发市场关注。该公司股价上涨主要受到其最新研究成果公布的利好消息推动。
根据公司公告，中国生物制药将在2025年美国临床肿瘤学会（ASCO）年会上公布45项最新研究成果，其中包括12项口头报告和4项重磅研究摘要（LBA）。这一消息展示了公司在肿瘤治疗研究领域的强劲实力，有望为公司未来发展带来积极影响。
值得注意的是，中国生物制药近期还传出其创新药物派安普利单抗在美国获得FDA批准的消息。该药物获批用于治疗复发或转移性鼻咽癌的一线治疗和用于以铂类为基础的化疗治疗失败的转移性鼻咽癌，成为公司首个在美国获批上市的创新药产品。这一系列利好消息进一步增强了投资者对公司研发实力和未来发展前景的信心，推动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.